Non-sleepy obstructive sleep apnoea: to treat or not to treat?

Eur Respir Rev. 2019 Dec 23;28(154):190031. doi: 10.1183/16000617.0031-2019. Print 2019 Dec 31.

Abstract

Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20-25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA and examines whether treating the condition leads to improvements in quality of life and reduced cardiometabolic dysfunction, comorbidities generally attributed to untreated obstructive sleep apnoea/hypopnoea syndrome.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aged
  • Clinical Decision-Making
  • Continuous Positive Airway Pressure / methods*
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Polysomnography / methods
  • Prognosis
  • Quality of Life*
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Severity of Illness Index
  • Sleep Apnea, Obstructive / diagnosis*
  • Sleep Apnea, Obstructive / epidemiology
  • Sleep Apnea, Obstructive / therapy*
  • Treatment Outcome
  • Watchful Waiting